• Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Home > News >

  • Dr Reddy's Lab drops on buzz surrounding Duvvada facility
  • January 03,2018  12:39
  • Meanwhile, the S&P BSE Sensex was up 39.46 points or 0.12% at 33,851.72.

    On the BSE, 52,000 shares were traded on the counter so far as against average daily volumes of 51,406 shares in the past one quarter. The stock had hit a high of Rs 2,415 and a low of Rs 2,299 so far during the day. The stock had hit a 52-week high of Rs 3,203.95 on 6 January 2017 and a 52-week low of Rs 1,901.65 on 11 August 2017.

    The stock had outperformed the market over the past one month till 2 January 2018, gaining 7.95% compared with the Sensex's 2.98% rise. The stock had, however, underperformed the market over the past one quarter, advancing 3.36% as against the Sensex's 8.08% rise. The scrip had also underperformed the market over the past one year, sliding 22.02% as against the Sensex's 27.14% rise.

    The large-cap company has equity capital of Rs 82.94 crore. Face value per share is Rs 5.

    According to a media report, an establishment inspection report (EIR) has been issued to Dr Reddy's Laboratories' Duvvada facility by the United States Food and Drug Administration. The report further stated that Duvvada facility status continues to be classified as official action initiated (OAI). In pharmaceuticals parlance, OAI means regulatory/admin sanctions by the drug regulator are initiated, as per reports.

    On a consolidated basis, Dr Reddy's Laboratories' net profit fell 1.1% to Rs 305.40 crore on 1.1% decline in net sales to Rs 3546 crore in Q2 September 2017 over Q2 September 2016.

    Dr Reddy's Laboratories is an integrated global pharmaceutical company.

    Powered by Capital Market - Live News

Follow us:

Disclaimer: Investment in securities and commodities market are subject to market risks, read all the related documents carefully before investing. SMC Global Securities Ltd. (CIN : U67120DL1997PLC188881): NSE INB/ INF/INE 230771431, BSE INB/INF 011343937, MSEI INB/INF 260771432, CDSL/NSDL-IN-DP-130-2015, SMC Research Analyst Registration- INH 100001849 I SMC Comtrade Ltd.: NCDEX/MCX (8200)/ NMCE/ICEX-INZ000035839 I SMC Investments and Advisors Ltd.: PMS INP000003435 I SMC Insurance Brokers Pvt. Ltd., IRDAI Regi: No: DB 272/04, License No. 289 Valid upto 27/01/2020 I Registered Office: 11/6B, Shanti Chamber, Pusa Road, New Delhi-110005, Tel.: (011) 30111000. For any complaints email – igc@smcindiaonline.com, website: www.smctradeonline.com

Insurance is the subject matter of solicitation • All insurance products sold through SMC Insurance Brokers Pvt. Ltd. • Investment Banking Services provided by SMC Capitals Ltd. • Equity PMS and Wealth management services provided by SMC Investments & Advisors Ltd. • IPOs and Mutual Funds distribution services are provided by SMC Global Securities Ltd. • Financing Services provided by Moneywise Financial Services Pvt Ltd. • Commodity broking services provided by SMC Comtrade Ltd. • Real Estate Advisory services are offered through SMC Real Estate Advisors Pvt. Ltd.

OUR OTHER WEBSITES Go
IMPORTANT LINKS Go
QUICK LINKS
Go

Toll-free : 1800-11-0909
Email: contact@smctradeonline.com

Sitemap
 
Copyright ©2016 SMC. All Rights Reserved | Disclaimer | Privacy Policy | RMS Policy | Copyright| Testimonials| Sitemap| Grievance| design agency: triverse| Powered by C-MOTS Infotech (ISO 9001:2015 certified)
Open An Account

Open my trading account now!  X 

* All fields are compulsory